Antifungal Resistance among Less Prevalent Candida Non-albicans and Other Yeasts versus Established and under Development Agents: A Literature Review

被引:13
作者
Espinel-Ingroff, Ana [1 ]
Canton, Emilia [2 ]
Peman, Javier [2 ,3 ]
机构
[1] VCU Med Ctr, Dept Med, Richmond, VA 23298 USA
[2] Hlth Res Inst Hosp La Fe, Severe Infect Res Grp, Valencia 46026, Spain
[3] Hosp Univ & Politecn La Fe, Dept Microbiol, Valencia 46026, Spain
关键词
non-prevalent Candida; antifungal resistance; new and established antifungal agents; Candida-non albicans; other yeast pathogens;
D O I
10.3390/jof7010024
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Fungal diseases and antifungal resistance continue to increase, including those caused by rare or emerging species. However, the majority of the published in vitro susceptibility data are for the most common fungal species. We reviewed the literature in order to pool reference minimal inhibitory concentration (MIC) data (Clinical and Laboratory Standards Institute-CLSI and European Committee on Antimicrobial Susceptibility-EUCAST) for rare/non-prevalent Candida and other yeast species. MIC results were compared with those for Candida albicans, C. glabrata, and C. krusei. Data were listed for twenty rare and emerging Candida spp., including C. auris, as well as two Cryptococcus spp., two Trichosporon spp., Saccharomyces cerevisiae and five Malassezia spp. The best detectors of antimicrobial resistance are the breakpoints, which are not available for the less common Candida species. However, epidemiological cutoff values (ECVs/ECOFFs) have been calculated using merely in vitro data for both reference methods for various non-prevalent yeasts and recently the CLSI has established ECVs for other Candida species. The ECV could identify the non-wild type (NWT or mutants) isolates with known resistance mechanisms. Utilizing these ECVs, we were able to report additional percentages of NWT, especially for non-prevalent species, by analyzing the MIC distributions in the literature. In addition, since several antifungal drugs are under development, we are listing MIC data for some of these agents.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 48 条
  • [1] Arendrup MC, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.00485-17, 10.1128/AAC.00485-17]
  • [2] EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents
    Arendrup, M. C.
    Meletiadis, J.
    Mouton, J. W.
    Guinea, J.
    Cuenca-Estrella, M.
    Lagrou, K.
    Howard, S. J.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (06) : 571.e1 - 571.e4
  • [3] Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs
    Arendrup, Maiken Cavling
    Jorgensen, Karin Meinike
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
  • [4] In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents
    Arendrup, Maiken Cavling
    Jorgensen, Karin Meinike
    Hare, Rasmus Kroger
    Chowdhary, Anuradha
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [5] Arendrup MC, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01225-18, 10.1128/aac.01225-18]
  • [6] Activity of novel antifungal compound APX001A against a large collection of Candida auris
    Berkow, Elizabeth L.
    Lockhart, Shawn R.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (11) : 3060 - 3062
  • [7] Drug resistance and tolerance in fungi
    Berman, Judith
    Krysan, Damian J.
    [J]. NATURE REVIEWS MICROBIOLOGY, 2020, 18 (06) : 319 - 331
  • [8] MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method
    Borman, Andrew M.
    Muller, Julian
    Walsh-Quantick, Jo
    Szekely, Adrien
    Patterson, Zoe
    Palmer, Michael D.
    Fraser, Mark
    Johnson, Elizabeth M.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (05) : 1194 - 1205
  • [9] Multicenter Comparison of the Etest and EUCAST Methods for Antifungal Susceptibility Testing of Candida Isolates to Micafungin
    Bougnoux, M. -E.
    Dannaoui, E.
    Accoceberry, I.
    Angoulvant, A.
    Bailly, E.
    Botterel, F.
    Chevrier, S.
    Chouaki, T.
    Cornet, M.
    Dalle, F.
    Datry, A.
    Dupuis, A.
    Fekkar, A.
    Gangneux, J. P.
    Guitard, J.
    Hennequin, C.
    Le Govic, Y.
    Le Pape, P.
    Maubon, D.
    Ranque, S.
    Sautour, M.
    Sendid, B.
    Chandenier, J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (08) : 5088 - 5091
  • [10] Azole susceptibility of Malassezia pachydermatis and Malassezia furfur and tentative epidemiological cut-off values
    Cafarchia, Claudia
    Iatta, Roberta
    Immediato, Davide
    Puttilli, Maria Rita
    Otranto, Domenico
    [J]. MEDICAL MYCOLOGY, 2015, 53 (07) : 743 - 748